We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-2.31%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.53B
AUM Growth
-$239M
Cap. Flow
-$4.03M
Cap. Flow %
-0.26%
Top 10 Hldgs %
79.89%
Holding
32
New
1
Increased
4
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
NAUT icon
Nautilus Biotechnolgy
NAUT
+$10.8M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$10.7M
3
DVAX
Dynavax Technologies
DVAX
+$7.96M
4
PANA
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
+$5.01M
5
TNGX icon
Tango Therapeutics
TNGX
+$4.74M

Top Sells

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$32.7M
2
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 88.31%
2 Financials 2.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$481M 31.49%
5,831,307
– –
AVIR icon
2
Atea Pharmaceuticals
AVIR
$420M
$121M 7.9%
5,615,659
– –
DVAX
3
DELISTED
Dynavax Technologies
DVAX
$116M 7.6%
11,771,708
+875,935
+8% +$7.96M
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$115M 7.53%
3,080,237
– –
ARQT icon
5
Arcutis Biotherapeutics
ARQT
$3.18B
$109M 7.12%
3,979,292
– –
ANNX icon
6
Annexon
ANNX
$886M
$73M 4.78%
3,241,628
– –
CCCC icon
7
C4 Therapeutics
CCCC
$412M
$62.1M 4.07%
1,642,209
– –
PHVS icon
8
Pharvaris
PHVS
$2.44B
$59.3M 3.88%
3,180,601
– –
MRSN
9
DELISTED
Mersana Therapeutics
MRSN
$50.2M 3.29%
147,827
– –
NRIX icon
10
Nurix Therapeutics
NRIX
$2.65B
$34.1M 2.23%
1,284,314
– –
CRNX icon
11
Crinetics Pharmaceuticals
CRNX
$8.92B
$31.7M 2.07%
1,679,701
+608,273
+57% +$10.7M
SYRS
12
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$31.5M 2.07%
578,504
– –
SLDB icon
13
Solid Biosciences
SLDB
$900M
$29M 1.9%
528,661
– –
MRNS
14
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$25.7M 1.68%
1,431,058
– –
APTX
15
DELISTED
Aptinyx Inc. Common Stock
APTX
$25.2M 1.65%
8,891,758
– –
KYMR icon
16
Kymera Therapeutics
KYMR
$8.94B
$23.3M 1.52%
479,605
– –
NAUT icon
17
Nautilus Biotechnolgy
NAUT
$115M
$20.2M 1.32%
2,000,000
+1,000,000
+100% +$10.8M
SVRA icon
18
Savara
SVRA
$1.19B
$19.8M 1.29%
11,622,598
– –
SYRE icon
19
Spyre Therapeutics
SYRE
$9.25B
$18.8M 1.23%
108,000
– –
BLUE
20
DELISTED
bluebird bio
BLUE
$17.2M 1.13%
41,547
– –
XFOR icon
21
X4 Pharmaceuticals
XFOR
$460M
$13.8M 0.9%
70,651
– –
TNGX icon
22
Tango Therapeutics
TNGX
$4.41B
$10.5M 0.69%
921,790
+421,790
+84% +$4.74M
RACB
23
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$10.1M 0.66%
1,000,000
– –
ARYD
24
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$7.5M 0.49%
700,000
– –
BLSA
25
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$5.13M 0.34%
487,500
– –
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q2 2021 Portfolio in Review

As of Q2 2021, Bain Capital Life Sciences Investors held 32 positions worth $1.53B, down 14% from $1.77B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Bain Capital Life Sciences Investors's Q2 2021 filing shows 1 new, 4 increased and 2 closed positions. Its largest new stake was Panacea Acquisition Corp. II Class A Ordinary Shares: 500,000 shares worth $5.01M. The largest sale was Constellation Pharmaceuticals, Inc., an estimated $32.7M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 92% a quarter earlier, followed by Financials.

  • Bain Capital Life Sciences Investors's largest Q2 2021 buy was Panacea Acquisition Corp. II Class A Ordinary Shares: 500,000 shares worth $5.01M.
  • Bain Capital Life Sciences Investors added most to Nautilus Biotechnolgy in Q2 2021, an estimated $10.8M increase.
  • Bain Capital Life Sciences Investors fully exited Constellation Pharmaceuticals, Inc. in Q2 2021, selling an estimated $32.7M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 80% of its $1.53B portfolio in Q2 2021.
  • Bain Capital Life Sciences Investors opened 1 new position and closed 2 in Q2 2021.
  • Bain Capital Life Sciences Investors's portfolio value fell 14% quarter-over-quarter to $1.53B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2021, filed 16 Aug 2021.